Articles

When measuring European regulatory approval, the timestamp matters

16th April 2014

When measuring European regulatory approval, the timestamp mattersDaniel Sanchez, MA and Yin Ho, MD, MBA

Daniel Sanchez and Yin Ho explore the concept of cycle time in regulatory decisions in the pharma industry and their significance in market access. They consider the FDA compared with... Read more

The impact of Western diseases on Latin America

15th April 2014

The impact of Western diseases on Latin AmericaLuke Sewell

Luke Sewell highlights the burden of Western diseases such as cancer, diabetes and obesity on Latin America in pharmaphorum's emerging markets themed month.How Western diseases are impacting Latin AmericaThe disease... Read more

Will pharma forsake emerging markets?

15th April 2014

Will pharma forsake emerging markets?Salil Kallianpur

In pharmaphorum's emerging markets themes month, Salil Kallianpur questions the importance of the emerging markets to the pharmaceutical industry.The post-9/11 world was a difficult place for both political and business... Read more

Don’t underestimate the potential of new products

14th April 2014

Don’t underestimate the potential of new productsJohn Ansell

John Ansell shows how much better the products launched a decade ago have performed than expected at the time, and considers the dangers of underestimating commercial potential.In the September 2003... Read more

News

US approval for Glaxo’s Tanzeum

16th April 2014

US approval for Glaxo’s TanzeumAndrew McConaghie

GlaxoSmithKline has gained FDA approval for its new diabetes treatment Tanzeum.The drug is the latest contender in the GLP-1 class of diabetes treatments, and is taken once a week for... Read more

Boehringer pursues aggressive new products strategy

16th April 2014

Boehringer pursues aggressive new products strategyPaul Tunnah

Boehringer Ingelheim announces flat growth for 2013 and anticipates a tough 2014, but pins future growth on aggressive R&D investment delivering more than 10 new product launches by 2016, to... Read more

Sovaldi ‘cost effective but not affordable’ for NHS

15th April 2014

Sovaldi ‘cost effective but not affordable’ for NHSAndrew McConaghie

A leading charity says new Hepatitis C drug Sovaldi is a huge step forward in treating the disease – but says its high price means it is not affordable for... Read more

New UK leader for ‘Innovation, Growth and Technology’

15th April 2014

New UK leader for ‘Innovation, Growth and Technology’Andrew McConaghie

The UK government has announced the creation of a new Director General for Innovation, Growth and Technology within the Department of Health.The new Director General would be a post for... Read more

Audio & Video

Rare Disease Day tweetchat

 

To view a full transcript of the discussion from this #hcsmeu tweetchat held on 28th February 2014 please click View more

Is there common ground for engagement be…

Doctors net webinar

 

The growth of online networks for doctors has been accompanied by recognition from the pharmaceutical industry that these digital meeting grounds can be... View more

Executive Perspectives: Jane Griffiths

 

In the latest in our series of interviews with senior executives who are steering the global pharma industry through a period of unparalleled change, pharmaphorum... View more

Full round table: Oncology shaping the …

 

Watch the full round table video debate on 'oncology shaping the... View more

White Papers

Who are the pharma social media butterfl…

Who are the pharma social media butterflies?Joanne Wunder, Caroline Howe, Andrea Visone and Laura Clewes

Social media has got everyone talking and it seems like everyone in pharma is talking about social media, so Ogilvy Healthworld figured it was time to analyse who were the... View info

Engage with confidence: Managing online …

Engage with confidence: Managing online adverse event reportingSiva Nadarajah

The pharmaceutical industry is waking up to the enormous potential offered by social media and other online data sources for informing better decisions around drug development and commercialization. Here, Siva... View info

Digital excellence in the global pharmac…

Digital excellence in the global pharmaceutical industry in 2014Tim van Tongeren and Dennis van Rooij

As pharmaceutical companies all look to step up their digital capabilities, this survey of digital leaders from across big pharma, exclusively first published on pharmaphorum, reveals an interesting picture of... View info

Patient research – the changing landscap…

Patient research – the changing landscape: Harnessing the voice of the citizen expertBrian Mondry and Jo Boxall

Empowered patients, or citizen experts as they are often called, are becoming one of the most powerful forces in healthcare, which means the pharmaceutical industry must learn to effectively engage... View info

Further News & Articles

Winds of change for pricing and funding in Spain (Part II)

In the concluding part of this two-part article exploring the drug pricing environment in Spain, Beatriz Casado and ... Read more

Articles

Winds of change for pricing and funding in Spain (Part I)

In part one of this two-part article exploring the drug pricing environment in Spain, Beatriz Casado and Kathrine Ka... Read more

Articles

AbbVie’s Hepatitis C drug works in difficult to treat patients

New data on AbbVie's three-pronged Hepatitis C treatment shows the combination helped patients whose infectio... Read more

News

Thailand pharmaceutical market update 2014

This article looks at the pharmaceutical market in Thailand in pharmaphorum's emerging market themed month.
Read more

Articles

Pharma access to UK patient records ‘still up for debate’

The decision about whether the pharma industry will be given access to anonymised patient records is still in... Read more

News

Measuring multi-channel marketing: metrics that matter

In the rush to use multi-channel marketing, don't forget ROI, says Deborah Runge.

Multi-channel mark... Read more

Articles